Conor Medsystems, Inc. And Cordis Corporation Release: Patient Enrollment Complete for Pivotal Trial of the NEVO(TM) Sirolimus-eluting Coronary Stent with Unique Reservoir Technology

WARREN, N.J.--(BUSINESS WIRE)--Cordis Corporation and Conor Medsystems, LLC announced today that patient enrollment has been completed for a randomized clinical trial comparing the NEVO™ Sirolimus-eluting Coronary Stent, a new cobalt chromium reservoir-based stent design, to the Taxus® Liberte® Paclitaxel-eluting Coronary Stent.